Biofourmis收购远程癌症监测初创公司Gaido Health
快速发展的波士顿医疗分析和数字疗法（DTx）初创公司
MedCity News报道，从武田制药手中收购了癌症监测公司Gaido Health的举动，这将使其能够扩展其产品组合和经营范围。
疗法（DTx）初创公司收购了武田制药的癌症监测公司Gaido Health
据MedCity News报道，这将使其能够扩展其产品组合和经营范围。
US Health Systems Are Applying Precision Medicine：
Biofourmis primarily focused on monitoring and treating patients with heart conditions via wearables
its AI-powered platform,
providing physicians a fuller picture into patients’ heart health and paving the way for more accurate, personalized care.
a recent Center for Connected Medicine survey：
But its move into oncology is a smart one, considering $151 billion is spent annually on cancer care in the US —
oncology tops the list of use cases for precision medicine among US health systems with initiatives underway, per a recent Center for Connected Medicine survey.
The Gaido Health purchase：
is the latest in a spate of activity signaling that Biofourmis is casting a wide net across the healthcare ecosystem —
which should benefit the startup both during the coronavirus pandemic and beyond.
Business Insider